Blog
RSS FeedPosted by Michael Wonder on 20 Dec 2024
ICER publishes fourth annual assessment of barriers to fair access within US commercial insurance prescription drug coverage
19 December 2024 - Most payers evaluated offer fair access across the domains reviewed; findings underscore the need for greater ...
Posted by Michael Wonder on 17 Dec 2024
ICER publishes final evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
16 December 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...
Posted by Michael Wonder on 12 Dec 2024
ICER announces most significant drug price hikes unsupported by new clinical evidence in US
12 December 2024 - Of 10 high expenditure drugs that had substantial 2023 net price increases, five were not supported ...
Posted by Michael Wonder on 10 Dec 2024
ICER releases draft evidence report on treatment for acute pain
9 December 2024 - Public comment period now open until 13 January 2025; requests to make oral comment during public ...
Posted by Michael Wonder on 28 Nov 2024
ICER to assess treatment for secondary progressive multiple sclerosis
19 November 2024 - Report will be subject of CTAF meeting in June 2025; draft scoping document open to public ...
Posted by Michael Wonder on 01 Nov 2024
ICER publishes evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
31 October 2024 - Current evidence suggests that tabelecleucel provides a substantial net health benefit when compared to usual care; ...
Posted by Michael Wonder on 22 Oct 2024
ICER publishes final evidence report on treatments for transthyretin amyloid cardiomyopathy
21 October 2024 - Independent appraisal committee voted that current evidence is adequate to demonstrate superior net health benefits for ...
Posted by Michael Wonder on 18 Sep 2024
The ICER developing special report for submission to CMS as part of public comment process on Medicare drug price negotiations
18 September 2024 - Report to reflect legislative specifications in the Inflation Reduction Act and subsequent CMS guidance regarding price ...
Posted by Michael Wonder on 17 Sep 2024
ICER to assess treatment for retinitis pigmentosa
17 September 2024 - Report will be subject of New England CEPAC meeting in April 2025; draft scoping document open ...
Posted by Michael Wonder on 12 Sep 2024
ICER releases draft evidence report on treatment for Epstein-Barr virus positive post-transplant lymphoproliferative disease
12 September 2024 - Public comment period now open until 8 October 2024; requests to make oral comment during public ...
Posted by Michael Wonder on 06 Sep 2024
ICER publishes evidence report on treatments for transthyretin amyloid cardiomyopathy
5 September 2024 - Current evidence suggests that tafamidis and acoramidis provide a net health benefit when compared to no ...
Posted by Michael Wonder on 22 Aug 2024
ICER publishes final evidence report on treatment for anaemia in myelodysplastic syndrome
22 August 2024 - Independent appraisal committee voted that current evidence is not adequate to demonstrate net health benefits for ...
Posted by Michael Wonder on 09 Aug 2024
BioMarin announces updated strategy for Roctavian to focus on US, Germany and Italy
5 August 2024 - Strategic focus will reduce operating expenses with the goal of achieving Roctavian profitability by end of 2025. ...
Posted by Michael Wonder on 30 Jul 2024
ICER to assess treatment for acute pain
29 July 2024 - Report will be subject of Midwest CEPAC meeting in February 2025; draft scoping document open to ...
Posted by Michael Wonder on 17 Jul 2024
ICER releases draft evidence report on treatments for transthyretin amyloid cardiomyopathy
17 July 2024 - Public comment period now open until 13 August 2024; requests to make oral comment during public ...